Report Description Table of Contents Primary Sclerosing Cholangitis Market: Treatment Revenue, Late-Stage Pipeline, Competitive Positioning and 2032 Outlook Prepared by Strategic Market Research SMR Executive Thesis- PSC remains a small but clinically intensive rare-liver-disease market. The central commercial question through 2032 is not whether disease prevalence will accelerate, but whether the market can shift from low-cost supportive pharmacotherapy toward higher-value PSC-specific medicines. Positive late-stage data from norucholic acid, a Phase III program for elafibranor, and Mirum's regulatory path for volixibat improve the opportunity set, while the failed Phase III PRIMIS study shows that clinical-endpoint risk remains unusually high. What Is the Primary Sclerosing Cholangitis Market Size and How Is the Therapeutic Landscape Changing? The Global Primary Sclerosing Cholangitis Market was valued at USD 0.19 billion in 2025 and is projected to reach USD 0.35 billion by 2032, expanding at a CAGR of 9.1% during 2026–2032, according to Strategic Market Research. Primary sclerosing cholangitis (PSC) is a rare chronic cholestatic liver disease in which inflammation and progressive scarring narrow or obstruct bile ducts inside and outside the liver. Companies such as Mirum Pharmaceuticals are developing volixibat for PSC-associated cholestatic pruritus, while Chemomab Therapeutics is advancing nebokitug (CM-101), an anti-CCL24 antibody being developed as a potential disease-modifying therapy for PSC. The PSC treatment market remains centered on supportive care and management of disease complications, with UDCA, antibiotics, pruritus therapies, and selective immunosuppressants accounting for most current treatment use. The absence of an FDA-approved PSC-specific drug leaves a significant commercial gap for disease-modifying therapies. Pipeline momentum is improving, led by volixibat, elafibranor, norucholic acid, and nebokitug, with late-stage development increasingly focused on pruritus control, biochemical improvement, and slowing disease progression in this underserved patient population. PSC represents a small but commercially concentrated orphan-disease opportunity about 70% of patients have IBD, and diagnosis is roughly twice as common in males, enabling targeted specialist identification. With up to 45% developing dominant strictures and a 10%–20% lifetime bile-duct cancer risk, unmet need, surveillance intensity, and complication burden support premium-value targeted therapies within hepatology and gastroenterology care networks. SMR Market Scope Note: This market is defined as pharmaceutical revenue directly associated with PSC management. It excludes MRCP, ERCP, biliary stents, transplantation, diagnostic testing revenue and investigational trial-drug value. The original 5% treatment bucket has therefore been refined to “Other & Emerging PSC-Specific Therapies”: its 2025 base represents other adjunctive pharmaceutical use not separately classified, while its forecast is the transition pool expected to absorb future PSC-specific branded launches if approved. Primary Sclerosing Cholangitis Market Snapshot: Treatment, Channel and Regional Highlights Treatment Type Ursodeoxycholic Acid: 45% share, USD 85.5 million in 2025 and 6.8% CAGR; it remains the largest pharmaceutical category because UDCA is deeply embedded in real-world PSC management despite uncertain disease-modifying benefit. Antibiotics: 18% share, USD 34.2 million and 7.5% CAGR; use is tied to bacterial cholangitis, infection around biliary obstruction and selected procedural episodes rather than chronic disease modification. Corticosteroids & Immunosuppressants: 12% share, USD 22.8 million and 6.2% CAGR; the segment is concentrated in PSC-autoimmune hepatitis overlap and selected associated immune-mediated conditions. Pruritus Management Therapies: 20% share, USD 38.0 million and 9.0% CAGR; this is a clinically important symptomatic category and the area where volixibat could create the clearest near-term branded differentiation if approved. Other & Emerging PSC-Specific Therapies: 5% share, USD 9.5 million and 28.0% CAGR; the 2025 base reflects other adjunctive pharmaceutical use, while the forecast assumes migration toward PSC-specific branded therapies as late-stage programs progress. Distribution Channel Hospital Pharmacies: 52% share, USD 98.8 million and 8.7% CAGR; leadership reflects specialist prescribing, inpatient infection management and the concentration of complex PSC care within tertiary hospital systems. Retail Pharmacies: 35% share, USD 66.5 million and 7.6% CAGR; the channel supports recurring outpatient prescriptions for UDCA, antibiotics and symptom-management medicines. Online Pharmacies: 13% share, USD 24.7 million and 14.0% CAGR; this is the fastest-growing channel because repeat oral prescriptions can increasingly be fulfilled through digital and home-delivery models, although future rare-disease launches may rely heavily on specialty-pharmacy infrastructure. Geography North America: 43% share, USD 81.7 million and 8.4% CAGR; the largest regional market is supported by specialist hepatology networks, transplant infrastructure and substantial clinical-development activity. Europe: 31% share, USD 58.9 million and 8.6% CAGR; the region combines mature PSC research networks with major late-stage assets from Dr. Falk Pharma and Ipsen. Asia-Pacific: 16% share, USD 30.4 million and 11.7% CAGR; it is the fastest-growing region in the SMR model as specialist access, case recognition and rare-liver-disease research broaden from a smaller base. Latin America: 6% share, USD 11.4 million and 9.4% CAGR; commercial activity remains centered on tertiary liver and gastroenterology services. Middle East & Africa: 4% share, USD 7.6 million and 9.0% CAGR; the region remains constrained by sparse epidemiological data and uneven access to advanced hepatology care. PSC Treatment Economics: From Established Supportive Therapy to Targeted Medicines Ursodeoxycholic acid accounted for 45% of the market, representing USD 85.5 million in 2025, and is projected to expand at a CAGR of 6.8% during 2026–2032. Its position reflects long-standing use, oral administration and familiarity among hepatologists rather than a proven ability to prevent transplantation or other major clinical outcomes. In the 2026 CALiD study, 51% of patients were prescribed UDCA at baseline, confirming that it remains a significant background therapy in contemporary practice. Late-stage programs from Ipsen and Dr. Falk Pharma are being developed in a treatment environment where UDCA is commonly present as background therapy, so successful targeted products may initially add to rather than immediately replace this category. [5, 10, 12] Antibiotics represented 18% of the market, equivalent to USD 34.2 million in 2025, and are forecast to grow at a CAGR of 7.5%. The category is episodic rather than disease-modifying: antibiotics are used when bacterial cholangitis occurs and can also be used around selected biliary interventions when infection risk is elevated. Because recurrent strictures and impaired bile drainage can create repeated infection episodes, this segment remains tied to complication burden even if targeted medicines enter the market. [3, 6] Corticosteroids and immunosuppressants held a 12% share, corresponding to USD 22.8 million in 2025, with a CAGR of 6.2%. Their role is concentrated in PSC-autoimmune hepatitis overlap and selected associated immune-mediated conditions rather than conventional large-duct PSC. This limits the segment's expansion relative to more targeted therapeutic categories and reinforces the importance of keeping general IBD drug spending outside the PSC market unless it is directly attributable to PSC-related overlap management. [6] Pruritus management therapies accounted for 20% of the market, representing USD 38.0 million in 2025, and are projected to grow at a CAGR of 9.0%. Cholestatic pruritus can materially impair quality of life and is treated with a range of symptom-directed medicines with variable response. This category now has a clear innovation catalyst: Mirum's investigational IBAT inhibitor volixibat reduces intestinal bile-acid reabsorption and, in the 158-patient Phase IIb VISTAS study, the company reported a 2.72-point improvement from baseline and a 1.64-point placebo-adjusted improvement in Adult ItchRO among the primary analysis population. FDA has granted Breakthrough Therapy designation for cholestatic pruritus due to PSC, but the product remains investigational. [7, 8, 9] Other & Emerging PSC-Specific Therapies represented 5% of the market, equal to USD 9.5 million in 2025, and are modeled to expand at a CAGR of 28.0%. To keep the commercial accounting defensible, SMR treats the 2025 base as other adjunctive pharmaceutical use not captured in the four major categories; investigational candidates are not counted as historical commercial sales. During the forecast period, however, this is the category most likely to absorb first-in-market PSC-specific branded therapies if approvals occur. The leading candidates use differentiated approaches, including PPAR-α/δ activation with elafibranor, modified bile-acid therapy with norucholic acid, anti-CCL24 signaling with nebokitug, live-biotherapeutic modulation with LB-P8 and NTCP inhibition with ABI-6250. [10, 11, 12, 14, 16, 17] The Commercially Addressable PSC Population: IBD Overlap, Disease Severity and Specialist Care Concentration The most commercially actionable PSC population is the diagnosed cohort already connected to hepatology, gastroenterology and IBD care. The 2026 meta-analysis estimated overall PSC prevalence at 8.06 per 100,000 but 15.2 per 1,000 among patients with IBD, with prevalence rising to 20.6 per 1,000 among people with ulcerative colitis. This concentration means IBD clinics provide a practical route for case identification, surveillance and potential future treatment initiation that is more targeted than general-population screening. [4] Large-duct disease is especially relevant to healthcare utilization. The same meta-analysis found large-duct PSC substantially more prevalent than small-duct PSC, while AASLD reports that up to 45% of patients may develop dominant biliary strictures. Patients with clinically significant strictures are more likely to require MRCP follow-up, ERCP-based intervention, antibiotic treatment and multidisciplinary assessment, increasing their healthcare intensity even though those procedural revenues are outside SMR's pharmaceutical market boundary. [4, 6] PSC-IBD also expands the surveillance pathway because colorectal-cancer risk is higher when both diseases coexist. NIDDK estimates that about 70% of people with PSC have IBD, but the CALiD study found that only around 30%–35% of PSC-IBD patients completed annual colonoscopy during follow-up. This care gap matters to pharmaceutical developers because trial recruitment and future prescribing depend on consistent specialist follow-up, yet real-world adherence to recommended monitoring is uneven. [1, 5] Advanced disease remains commercially important because transplantation is still the definitive treatment for selected patients with liver failure or severe complications. A 2026 meta-analysis of 29 studies involving 4,682 patients transplanted for PSC found recurrent PSC in 18.66% after transplantation. A medicine capable of delaying progression or reducing major biliary complications would therefore address a clinically meaningful outcome beyond laboratory improvement, although no current investigational therapy should be assumed to deliver that benefit until confirmed in adequately designed trials. [18] PSC Pipeline Frontier: Late-Stage Therapies Poised to Reshape the Treatment Market The PSC pipeline is moving toward a more investable late-stage profile, although regulatory timing differs materially across assets. Mirum Pharmaceuticals’ volixibat has delivered positive Phase IIb pruritus data and received FDA Breakthrough Therapy and orphan-drug designations, positioning it as a relatively near-term opportunity, although the FDA’s recommendation for an additional Phase III study adds filing uncertainty. Ipsen’s elafibranor has advanced into the approximately 350-patient Phase III ELASCOPE trial after Phase II ELMWOOD demonstrated meaningful ALP reductions, supporting its potential as a disease-focused entrant. Dr. Falk Pharma’s norucholic acid currently has one of the strongest PSC-specific datasets, with its pivotal Phase III study showing a 15.1% response versus 4.2% with placebo alongside histological improvement. Chemomab’s nebokitug offers a differentiated anti-fibrotic mechanism, but Phase III progression depends on securing a development partner, making commercialization timing less predictable. Beyond these leaders, LB-P8, ABI-6250, and TAK-781 are expanding the mid-stage pipeline across microbiome, bile-acid transport, and other novel mechanisms. Collectively, these programs strengthen the probability of multiple differentiated treatment options entering the PSC market over the forecast period. PSC Pharmaceutical Distribution Landscape: Hospital Leadership and the Shift Toward Specialty Fulfillment Hospital pharmacies accounted for 52% of the Primary Sclerosing Cholangitis Market, representing USD 98.8 million in 2025, and are projected to expand at a CAGR of 8.7%. The channel leads because complex PSC is managed through tertiary hepatology and gastroenterology systems where patients may receive specialist-initiated prescriptions, treatment for bacterial cholangitis and medications linked to inpatient or high-acuity care. This market-share rationale is pharmaceutical only: ERCP, stenting, imaging and transplantation are important clinical utilization drivers but are excluded from the distribution-channel revenue calculation. [3, 6] Retail pharmacies represented 35% of the market, equivalent to USD 66.5 million in 2025, and are expected to expand at a CAGR of 7.6%. The channel supports repeat outpatient prescriptions for UDCA, antibiotics used outside the hospital setting and medicines for pruritus or associated conditions. Its growth is steadier than online fulfillment because current therapy is dominated by established oral medicines rather than newly launched specialty products. Online pharmacies held a 13% market share, corresponding to USD 24.7 million in 2025, and are projected to expand at a CAGR of 14.0%. The channel benefits from refill convenience and home delivery for long-duration oral therapy. The future mix may become more complex if PSC-specific branded products launch: rare-disease medicines are often initiated by specialists and may use dedicated specialty-pharmacy networks even when fulfillment is remote, so “online” should be interpreted as digital/mail-order dispensing rather than unrestricted direct-to-consumer access. Global PSC Market Opportunity: Regional Leadership, Access Gaps and Commercial Expansion North America accounted for 43% of the global market, representing USD 81.7 million in 2025, and is projected to expand at a CAGR of 8.4%. The region combines specialist hepatology centers, IBD referral networks, advanced imaging and transplant infrastructure with an active PSC clinical-development ecosystem. The CALiD study drew 1,300 patients from 19 North American centers, while Mirum's volixibat regulatory strategy and LISCure's LB-P8 Phase II trial illustrate current development activity. This makes North America the most immediately actionable launch environment if the first PSC-specific therapies reach approval. [5, 7, 16] Europe represented 31% of the market, equivalent to USD 58.9 million in 2025, and is forecast to grow at a CAGR of 8.6%. Europe has mature PSC academic networks and substantial participation in long-term liver-disease research. Dr. Falk Pharma's pivotal NUC-5 program and Ipsen's ELASCOPE program give the region particular strategic importance for disease-modifying development. Country-level reimbursement assessment could, however, create more variable launch sequencing than in the United States. [11, 12] Asia-Pacific held 16% of the market, corresponding to USD 30.4 million in 2025, and is projected to record the fastest regional CAGR at 11.7%. The 2026 epidemiology meta-analysis shows substantial geographic heterogeneity and cautions against applying a single prevalence assumption across countries. Commercial expansion is therefore more likely to come from better case ascertainment, specialist hepatology access and participation in multinational rare-disease development than from a uniform regional prevalence trend. [4] Latin America accounted for 6% of the market, representing USD 11.4 million in 2025, with a CAGR of 9.4%. The practical commercial base is concentrated around tertiary hospitals, transplant centers and specialist gastroenterology networks rather than broad primary-care prescribing. Limited population-based epidemiology makes patient identification less predictable, so partnerships with major referral centers and IBD specialists are likely to be more important than population-scale promotion. The Middle East & Africa represented 4% of the market, equivalent to USD 7.6 million in 2025, and are projected to expand at a CAGR of 9.0%. The region remains underrepresented in PSC epidemiology and clinical-development datasets, while access to MRCP, advanced endoscopy and transplant services varies widely. Near-term commercialization is therefore likely to be concentrated in higher-capability urban liver centers rather than evenly distributed across the region. [4] Primary Sclerosing Cholangitis Competitive Landscape: Clinical Differentiation, Pipeline Readiness and Market Positioning Competition in PSC is no longer a single-class race. Companies are pursuing different value propositions: symptom relief, bile-acid regulation, clinical disease modification, anti-fibrotic signaling and microbiome or transporter-based approaches. The most useful way to read the landscape is therefore through several complementary views rather than one undifferentiated company list. Competitive View 1 – Strategic Positioning by Clinical Objective Strategic Position Company Lead PSC Asset Development Status Commercial Relevance Pruritus-focused entry Mirum Pharmaceuticals Volixibat Phase IIb completed; FDA discussions ongoing Potentially clear symptom-based label; regulatory path remains uncertain after FDA recommended Phase III. Broad disease modification Ipsen Elafibranor Phase III ELASCOPE recruiting Event-driven study could support broader value than a symptom-only therapy if progression benefit is shown. Biochemical + histological disease focus Dr. Falk Pharma Norucholic acid Pivotal Phase III positive; long-term/open-label Phase III continuing One of the strongest late-stage datasets; regulatory interpretation will be decisive. Anti-fibrotic immune pathway Chemomab Nebokitug Phase II completed; Phase III partner-dependent Differentiated anti-CCL24 mechanism, but timing is constrained by partnership strategy. Gut-liver / live biotherapeutic LISCure Biosciences LB-P8 Phase II recruiting Adds microbiome-based differentiation but remains earlier-stage. Bile-acid uptake / transporter Assembly Biosciences ABI-6250 Phase II planned for Q1 2027 NTCP inhibition broadens mechanism diversity; too early for base-case commercial assumptions. Competitive View 2 – Development Readiness and Market Timing Readiness Tier Assets / Companies What to Watch SMR Interpretation Near-term regulatory opportunity Volixibat – Mirum Further FDA discussions; potential NDA submission targeted H1 2027 Fastest potential branded symptom entry, but another Phase III request remains a material risk. Pivotal / Phase III disease-focused Norucholic acid – Dr. Falk; Elafibranor – Ipsen Long-term NUC-5 data; ELASCOPE event accrual These programs are most important for proving disease modification rather than symptom relief alone. Phase III option, execution dependent Nebokitug – Chemomab Partnering and corporate prioritization Scientific differentiation is intact; development timing is not. Mid-stage watchlist LB-P8 – LISCure; ABI-6250 – Assembly Phase II recruitment/initiation and biomarker signal Could become next-wave competitors if early biological effects translate into clinically relevant outcomes. Early-stage exploratory TAK-781 – Takeda Safety, PK/PD and target-engagement data in PSC cohort Too early to influence current revenue, but notable because a large biopharma remains active in PSC. Late-stage failure benchmark Cilofexor – Gilead PRIMIS showed no significant fibrosis benefit Important precedent for endpoint risk and the gap between biochemical activity and true disease modification. Competitive View 3 – Company-by-Company Portfolio Positioning Mirum Pharmaceuticals Mirum's PSC strategy centers on volixibat, an investigational oral IBAT inhibitor being developed for cholestatic pruritus. The VISTAS result gives the company a differentiated symptom-focused proposition, while FDA Breakthrough Therapy and orphan-drug designations increase regulatory visibility without constituting approval. Mirum also commercializes rare-liver-disease products including LIVMARLI, CHOLBAM and CTEXLI, giving it an established specialist commercial infrastructure that could support a PSC launch if volixibat reaches approval. [7, 8, 9] Ipsen Ipsen is developing elafibranor through the Phase III ELASCOPE program after favorable Phase II ELMWOOD biochemical data. The drug's dual PPAR-α/δ activity differentiates it from IBAT inhibition and anti-fibrotic antibody approaches. Ipsen already markets elafibranor as Iqirvo for primary biliary cholangitis, which provides cholestatic-liver-disease experience, but PSC remains an investigational indication and ELASCOPE must establish independent clinical benefit. [10, 11, 20] Dr. Falk Pharma Dr. Falk Pharma is positioned around norucholic acid, which has one of the most advanced disease-focused datasets in PSC. The pivotal NUC-5 program showed superiority over placebo on a combined biochemical and histological endpoint at 96 weeks, and long-term plus open-label Phase III follow-up is continuing. If regulators view those endpoints as sufficient to support a clinically meaningful benefit, NCA could become a major benchmark for subsequent PSC development. [12, 13] Chemomab Therapeutics Chemomab's nebokitug is differentiated by anti-CCL24 biology aimed at fibro-inflammatory signaling. Phase II development established a basis for a potential Phase III program, but the August 2026 corporate update makes future PSC execution dependent on securing a partner while rheumatoid arthritis receives near-term prioritization. The key competitive variable is therefore financing and partnering rather than mechanism alone. [14, 22] LISCure Biosciences LISCure is developing LB-P8 as a live biotherapeutic in a recruiting Phase II PSC trial with an estimated 87 participants. FDA previously granted orphan-drug designation to the single-strain live biotherapeutic for PSC. The program provides a distinct gut-liver-axis approach and is strategically relevant as an example of pipeline diversification beyond conventional small molecules and antibodies. [16, 23] Assembly Biosciences Assembly Biosciences plans to expand ABI-6250, an oral NTCP inhibitor, into a Phase II study focused on PBC and PSC in the first quarter of 2027. The asset remains investigational and has not been approved anywhere globally. Its importance to the PSC landscape is currently as a next-wave transporter-based program rather than a near-term commercial competitor. [17] Takeda and Other Early Programs Takeda is recruiting a Phase I study of TAK-781 that includes participants with non-cirrhotic large-duct PSC, with an estimated total enrollment of 134 across the broader healthy-volunteer and PSC program. Earlier-stage and completed PSC programs from other developers remain useful as scientific precedents, but they should not be weighted equally with the current Phase III and pivotal-stage assets when assessing near-term market share shifts. [24] Primary Sclerosing Cholangitis Market Outlook to 2032: Catalysts, Competitive Shifts and Forecast Risks The biggest commercial inflection is the potential arrival of the first PSC-specific branded medicines. SMR's 9.1% market CAGR therefore reflects a change in treatment mix more than a change in disease prevalence. If one or more late-stage programs secure approval, revenue could shift toward specialist-priced therapy even if the number of diagnosed patients grows only gradually. The market will not necessarily converge on a single winner. Volixibat is pursuing a symptom-defined pruritus population, whereas elafibranor and norucholic acid are attempting to establish broader disease-focused value. Nebokitug targets fibro-inflammatory biology, while LB-P8 and ABI-6250 introduce different mechanistic routes. This creates the possibility of segmentation by symptom burden, biochemical phenotype, fibrosis risk, prior therapy and eventual combination or sequential use rather than simple class replacement. The largest forecast risk is clinical rather than epidemiological. PRIMIS demonstrated that a large Phase III PSC study can fail despite a plausible mechanism and prior biological activity. Slow disease progression, heterogeneous natural history, limited rare-disease recruitment pools and uncertainty around surrogate endpoints can extend development timelines or reduce the probability of approval. For investors and corporate strategy teams, the most important milestones are therefore not only trial starts but clinically meaningful endpoint readouts and regulator feedback. [15] Commercial Catalysts and Risks to Monitor Catalyst / Risk Why It Matters Expected Market Effect Volixibat FDA pathway Determines whether symptom-focused branded PSC treatment can reach review without an additional full Phase III program. Could create the first major branded pruritus revenue pool; delay would push value later in the forecast. NUC-5 long-term and regulatory interpretation Tests whether biochemical plus histological benefit can support broader disease-focused positioning. Potentially reshapes the “other & emerging” category toward disease-modifying therapy. ELASCOPE event accrual A clinical-event endpoint may provide stronger evidence than short-term ALP changes. Could support premium positioning if progression benefit is demonstrated, but study duration is long. Partnering for nebokitug Determines whether a differentiated anti-fibrotic program advances to Phase III in PSC. Upside scenario if partnered; limited forecast impact if development remains deferred. Next-wave Phase II programs LB-P8 and ABI-6250 test whether microbiome and transporter strategies produce reproducible biological signals. Broadens post-2030 competition if mid-stage results are positive. Endpoint failure risk PRIMIS shows that mechanism and biochemical response do not guarantee fibrosis benefit. Supports conservative probability-weighting of pipeline-driven revenue. For Strategic Market Research, the most defensible interpretation is that PSC remains a specialist, low-volume market with a disproportionate clinical burden and an improving—but still high-risk—therapeutic pipeline. The projected expansion from USD 0.19 billion in 2025 to USD 0.35 billion by 2032 depends on successful conversion of part of the current supportive-care market into higher-value targeted therapy, while UDCA, antibiotics, symptom management and specialty dispensing remain important throughout the forecast period. SMR Research Methodology, Market Definition and Source Transparency Strategic Market Research treats the 2025 market value, 2032 forecast, global CAGR, segment shares, segment market sizes, segment CAGRs, distribution-channel values and regional values in this report as proprietary SMR market estimates supplied for this research description. External market-research-company estimates were not used to set or validate these figures. The market scope is pharmaceutical treatment revenue directly associated with PSC management. Diagnostics, imaging, endoscopy, biliary devices, hospital procedures and liver transplantation are discussed only as clinical and commercial context and are excluded from market revenue. General IBD drug spending is also excluded unless directly attributable to PSC-related overlap management. Investigational clinical-trial drugs are not counted as 2025 commercial sales. Primary Sclerosing Cholangitis Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 0.19 Billion Revenue Forecast in 2032 USD 0.35 Billion Overall Growth Rate CAGR of 9.1% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Treatment Type, By Distribution Channel, By Geography By Treatment Type Ursodeoxycholic Acid, Antibiotics, Corticosteroids & Immunosuppressants, Pruritus Management Therapies, Other & Emerging PSC-Specific Therapies By Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, Japan, China, India, South Korea, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Absence of FDA-approved PSC-specific medicines, progression of late-stage targeted therapies, high complication and surveillance burden, specialist concentration within hepatology and gastroenterology networks, expansion of pruritus-directed treatment, and increasing specialty-pharmacy fulfillment Customization Option Available upon request Frequently Asked Question About This Report Q1. What role does innovation play in market development? A1. Innovation is shifting the treatment landscape from supportive medicines toward therapies designed for specific symptoms or disease pathways. Volixibat, norucholic acid, elafibranor, nebokitug, and newer transporter or microbiome approaches could create distinct branded treatment positions if clinical development succeeds. Q2. What factors should businesses consider before entering this market? A2. Companies need to account for the small diagnosed population, specialist-centered prescribing, long clinical-development timelines, and uncertainty around acceptable trial endpoints. Strong hepatology networks, rare-disease commercialization capabilities, reimbursement planning, and a clearly differentiated clinical benefit are especially important. Q3. Why are companies investing in advanced solutions in the industry? A3. There is currently no FDA-approved disease-specific therapy, leaving substantial unmet need for products that improve symptoms or slow progression. A successful targeted therapy could capture significantly more value per patient than established low-cost supportive treatments. Q4. What factors are encouraging adoption across different healthcare settings in the market? A4. Adoption is supported by concentrated specialist care, significant complication burden, and overlap with inflammatory bowel disease that helps identify patients through gastroenterology networks. Future branded therapies could also benefit from specialty-pharmacy fulfillment and established rare-liver-disease centers. Q5. What are the most promising applications expected to grow in the industry? A5. Cholestatic pruritus represents one of the clearest near-term opportunities because volixibat is being developed specifically around this high-burden symptom. Broader disease-modifying treatment could represent an even larger opportunity if norucholic acid, elafibranor, or other candidates demonstrate clinically meaningful effects on disease progression. Q6. What are the biggest challenges affecting market expansion? A6. Clinical-development risk remains unusually high because disease progression is slow and heterogeneous, while surrogate endpoints may not translate into meaningful long-term benefit. Small recruitment pools, uncertain regulatory pathways, and previous Phase III failures also make pipeline-driven growth less predictable. Sources: [1] NIDDK — Primary Sclerosing Cholangitis: Definition & Facts [2] NIDDK — Diagnosis of Primary Sclerosing Cholangitis [3] NIDDK — Treatment for Primary Sclerosing Cholangitis [4] Ho et al., Hepatology International (2026) — Epidemiology of PSC in general and IBD populations [5] Liver International (2026) — CALiD North American PSC care study [6] AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma [7] Mirum Pharmaceuticals — Q2 2026 Financial Results and Business Update [8] Mirum Pharmaceuticals — VISTAS Phase IIb Topline Results [9] FDA Orphan Drug Database — Volixibat for PSC [10] Journal of Hepatology / PubMed — ELMWOOD Phase II elafibranor study [11] ClinicalTrials.gov — ELASCOPE Phase III elafibranor study (NCT07387549) [12] Dr. Falk Pharma — Positive pivotal Phase III NUC-5 results for norucholic acid [13] ClinicalTrials.gov — Open-label Phase III norucholic acid study (NCT06886360) [14] Chemomab Therapeutics — Q2 2026 Corporate Update [15] PubMed — Phase III PRIMIS trial of cilofexor in non-cirrhotic PSC [16] ClinicalTrials.gov — LB-P8 Phase II PSC study (NCT06699121) [17] Assembly Biosciences — ABI-6250 expansion into PBC and PSC [18] Liver International (2026) — PSC recurrence after liver transplantation meta-analysis [19] ClinicalTrials.gov — VISTAS volixibat study (NCT04663308) [20] FDA Orphan Drug Database — Elafibranor for PSC [21] FDA Orphan Drug Database — Norucholic acid for PSC [22] ClinicalTrials.gov — SPRING Phase II nebokitug/CM-101 study (NCT04595825) [23] FDA Orphan Drug Database — LISCure live biotherapeutic for PSC [24] ClinicalTrials.gov — Takeda TAK-781 Phase I study (NCT07229911 Table of Contents - Global Primary Sclerosing Cholangitis Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Distribution Channel, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Distribution Channel, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type and Distribution Channel Investment Opportunities in the Primary Sclerosing Cholangitis Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Pruritus Management Therapies, PSC-Specific Disease-Modifying Therapies, Specialty Pharmacy Fulfillment, and Targeted Rare-Liver-Disease Treatment Programs Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Primary Sclerosing Cholangitis Therapies in Rare-Liver-Disease Management and Specialist Hepatology Care Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Clinical Development Factors Role of Disease-Modifying Therapies, Pruritus Management, Specialty Care, and Rare-Disease Drug Development in Market Expansion Clinical Endpoint Selection, Patient Recruitment, Regulatory Uncertainty, and Long-Term Disease Progression Trends in PSC Drug Development Global Primary Sclerosing Cholangitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Ursodeoxycholic Acid Antibiotics Corticosteroids & Immunosuppressants Pruritus Management Therapies Other & Emerging PSC-Specific Therapies Market Analysis by Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Primary Sclerosing Cholangitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type and Distribution Channel Country-Level Breakdown: United States Canada Mexico Europe Primary Sclerosing Cholangitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type and Distribution Channel Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Primary Sclerosing Cholangitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type and Distribution Channel Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Primary Sclerosing Cholangitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type and Distribution Channel Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Primary Sclerosing Cholangitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type and Distribution Channel Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Mirum Pharmaceuticals, Inc. Ipsen Dr. Falk Pharma GmbH Chemomab Therapeutics Ltd. LISCure Biosciences Assembly Biosciences, Inc. Takeda Pharmaceutical Company Limited Gilead Sciences, Inc. Intercept Pharmaceuticals CymaBay Therapeutics Shire Pharmaceuticals Enanta Pharmaceuticals, Inc. Competitive Landscape and Strategic Insights Benchmarking Based on Clinical Development Stage, Mechanism of Action, Regulatory Readiness, Specialist Commercial Infrastructure, Trial Execution Capability, and Regional Presence Pipeline Qualification and Regulatory Development Capability Analysis Late-Stage PSC-Specific Therapy Positioning Pruritus Management and Disease-Modifying Therapy Competitiveness Specialty Pharmacy, Hospital Distribution, and Specialist Prescribing Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Treatment Type, Distribution Channel, and Geography (2026–2032) Regional Market Breakdown by Treatment Type and Distribution Channel (2026–2032) Competitive Benchmarking of Leading Vendors and Pipeline Developers Regulatory, Clinical Development, and Commercialization Risk Analysis Therapeutic Development Trends Across Ursodeoxycholic Acid, Antibiotics, Corticosteroids & Immunosuppressants, Pruritus Management Therapies, and Other & Emerging PSC-Specific Therapies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Treatment Type and Distribution Channel (2025 vs. 2032) Global Primary Sclerosing Cholangitis Therapeutic Ecosystem and Value Chain Analysis